Caribou Biosciences Stock Analysis
CRBU Stock | USD 0.77 0.02 2.53% |
Caribou Biosciences is undervalued with Real Value of 3.88 and Target Price of 13.25. The main objective of Caribou Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Caribou Biosciences is worth, separate from its market price. There are two main types of Caribou Biosciences' stock analysis: fundamental analysis and technical analysis.
The Caribou Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Caribou Biosciences is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Caribou Stock trading window is adjusted to America/New York timezone.
Caribou |
Caribou Stock Analysis Notes
About 62.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Caribou Biosciences has Price/Earnings To Growth (PEG) ratio of 0.5. The entity recorded a loss per share of 1.65. The firm had not issued any dividends in recent years. Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Caribou Biosciences please contact Rachel Haurwitz at 510 982 6030 or go to https://cariboubio.com.Caribou Biosciences Quarterly Total Revenue |
|
Caribou Biosciences Investment Alerts
Caribou Biosciences generated a negative expected return over the last 90 days | |
Caribou Biosciences has some characteristics of a very speculative penny stock | |
Caribou Biosciences has high historical volatility and very poor performance | |
Caribou Biosciences has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 9.99 M. Net Loss for the year was (149.1 M) with loss before overhead, payroll, taxes, and interest of (119.56 M). | |
Caribou Biosciences currently holds about 339.92 M in cash with (138.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Caribou Biosciences has a poor financial position based on the latest SEC disclosures | |
Roughly 62.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from news.google.com: Caribou Biosciences, Inc. Investigation Bronstein, Gewirtz Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com |
Caribou Biosciences Upcoming and Recent Events
14th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
14th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Caribou Largest EPS Surprises
Earnings surprises can significantly impact Caribou Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.4105 | -0.46 | -0.0495 | 12 | ||
2022-03-21 | 2021-12-31 | -0.36 | -0.31 | 0.05 | 13 | ||
2024-11-07 | 2024-09-30 | -0.4494 | -0.3815 | 0.0679 | 15 |
Caribou Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.7 M | State Street Corp | 2024-12-31 | 1.7 M | Fmr Inc | 2024-12-31 | 1.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.5 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.2 M | Two Sigma Investments Llc | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 1.1 M | Point72 Asset Management, L.p. | 2024-12-31 | 1 M | Fidelity International Ltd | 2024-12-31 | 860.7 K | Blackrock Inc | 2024-12-31 | 6.6 M | Pfizer Inc | 2024-12-31 | 4.7 M |
Caribou Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.38 M.Caribou Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.48) | (0.50) | |
Return On Capital Employed | (0.59) | (0.62) | |
Return On Assets | (0.48) | (0.50) | |
Return On Equity | (0.59) | (0.62) |
Management Efficiency
Caribou Biosciences has return on total asset (ROA) of (0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4799) %, meaning that it created substantial loss on money invested by shareholders. Caribou Biosciences' management efficiency ratios could be used to measure how well Caribou Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.5 in 2025. Return On Capital Employed is likely to drop to -0.62 in 2025. Non Current Liabilities Total is likely to gain to about 30.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 24.8 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.80 | 2.52 | |
Tangible Book Value Per Share | 2.80 | 2.56 | |
Enterprise Value Over EBITDA | (0.92) | (0.97) | |
Price Book Value Ratio | 0.57 | 0.54 | |
Enterprise Value Multiple | (0.92) | (0.97) | |
Price Fair Value | 0.57 | 0.54 | |
Enterprise Value | 153.8 M | 146.1 M |
Caribou Biosciences' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Technical Drivers
As of the 5th of April, Caribou Biosciences shows the Standard Deviation of 4.41, risk adjusted performance of (0.27), and Mean Deviation of 3.44. Caribou Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Caribou Biosciences Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Caribou Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Caribou Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Caribou Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Caribou Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Caribou Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Caribou Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Caribou Biosciences Outstanding Bonds
Caribou Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Caribou Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Caribou bonds can be classified according to their maturity, which is the date when Caribou Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Caribou Biosciences Predictive Daily Indicators
Caribou Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Caribou Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Caribou Biosciences Forecast Models
Caribou Biosciences' time-series forecasting models are one of many Caribou Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Caribou Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Caribou Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Caribou Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Caribou shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Caribou Biosciences. By using and applying Caribou Stock analysis, traders can create a robust methodology for identifying Caribou entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (14.92) | (14.17) | |
Operating Profit Margin | (16.67) | (15.84) | |
Net Loss | (14.92) | (14.17) | |
Gross Profit Margin | (2.03) | (1.92) |
Current Caribou Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Caribou analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Caribou analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
13.25 | Strong Buy | 9 | Odds |
Most Caribou analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Caribou stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Caribou Biosciences, talking to its executives and customers, or listening to Caribou conference calls.
Caribou Stock Analysis Indicators
Caribou Biosciences stock analysis indicators help investors evaluate how Caribou Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Caribou Biosciences shares will generate the highest return on investment. By understating and applying Caribou Biosciences stock analysis, traders can identify Caribou Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 51.2 M | |
Common Stock Shares Outstanding | 90.3 M | |
Total Stockholder Equity | 253 M | |
Tax Provision | -9000.00 | |
Property Plant And Equipment Net | 39.3 M | |
Cash And Short Term Investments | 209.5 M | |
Cash | 16.3 M | |
Accounts Payable | 2.5 M | |
Net Debt | 10.2 M | |
50 Day M A | 1.1682 | |
Total Current Liabilities | 30.7 M | |
Other Operating Expenses | 176.6 M | |
Non Current Assets Total | 93.9 M | |
Non Currrent Assets Other | 45.4 M | |
Stock Based Compensation | 16.7 M |
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.